Hopkins Researchers Report Lack Of Education And Counseling For Patients Undergoing Gene Testing

March 20, 1997

Results of a nationwide survey of physicians and genetic counselors conducted by researchers at the Johns Hopkins Medical Institutions show that most patients who underwent genetic testing for a gene linked with colon cancer did not receive adequate genetic counseling or give their written informed consent for the test. Additionally, the researchers found that nearly one-third of the physicians surveyed did not recognize the test's limitations and without intervention would have incorrectly interpreted the test results for their patients. These findings are reported in the March 20, 1997 issue of the New England Journal of Medicine.

"This study is unique because it is one of the first to evaluate the use of a gene test in the commercial setting," says Francis Giardiello, MD, associate professor of medicine and lead author of the study. "Before genetic testing for cancer susceptibility became available commercially, the tests were offered in a research environment and delivered according to controlled protocols. Because many patients are now receiving the test from their personal physicians however, we were interested in how well patients not involved in research programs were being informed of the benefits and limitations of the test," says Giardiello. "The survey confirmed our concerns that there were inadequacies in the genetic testing process."

Patients involved in this survey were tested for a mutation of the APC gene, a tumor suppressor gene found to be linked to colon cancer by Hopkins researchers in 1991. A positive test for an APC gene mutation indicates that the affected individual has an inherited genetic condition called familial adenomatous polyposis (FAP). This condition is characterized by the formation of hundreds of polyps in the colon. If prophylactic surgery is not performed, nearly all patients with FAP go on to develop colorectal cancer later in life.

To assess the test's use, the Hopkins researchers conducted phone interviews with physicians and/or genetic counselors who had ordered the test through LaboratoryCorporation of America (LabCorp). The Johns Hopkins University has a service contract with LabCorp to provide guidance to physicians concerning test interpretation, patient education and counseling. Information gathered as a result of these activities allowed the researchers to assess the test in three areas: 1) validity of test indications 2) provision of formal pre-test genetic counseling and written informed consent of the patient, and 3) understanding by providers of the test results.

The Hopkins researchers found that of the 177 patients who received testing, 83 percent (147) had valid indications for testing, which included having symptoms of FAP or being a first-degree relative of FAP-affected patients. Of the patients tested, only 19 percent (33) received genetic counseling prior to testing and 17 percent (28) gave their written informed consent to have the test performed. Furthermore, in 32 percent of the cases, the physicians did not know how to interpret the test results.

Based on these findings, researchers recommended that a comprehensive approach to patient counseling and education be universally implemented. "Physicians who plan to order this test for their patients must be prepared to offer or arrange for genetic counseling for their patients," says Jill Brensinger, MS, a genetic counselor with the Hereditary Colorectal Cancer Registry at Johns Hopkins and co-investigator of the study. "Patients need to know that a positive test result indicates the need for routine colon surveillance, eventual prophylactic surgery and possible discussions on family planning. Additionally, physicians need to be educated that a test reporting that no mutation was found could be a false negative if no mutation was previously detected in another family member," says Brensinger. "If patients are not informed of this possibility, they may not adopt the appropriate surveillance practices and their disease will not be detected in its earliest stage."

Familial adenomatous polyposis affects one of every 8,000 individuals, accounting for about one percent of all colon cancers. Approximately 131,000 new cases of colon cancer will be diagnosed in the U.S. this year alone. An additional 37,000 will die from the disease. It is the third most common cancer diagnosed in both men and women.

In addition to Giardiello and Brensinger, other participants in this research study include Gloria M. Petersen, PhD, Michael C. Luce, PhD, Linda M. Hylind, BS, RN, Judith A. Bacon, BS, Susan V. Booker, BA, and Rodger D. Parker, PhD, Stanley R. Hamilton, MD.

Johns Hopkins Medicine

Related Colon Cancer Articles from Brightsurf:

New prognostic markers for colon cancer identified
The study recently published by MedUni Vienna and collaborative partners nominates ILSs as novel prognostic players orchestrating the pathobiology of metastatic colorectal cancer.

Turning colon cancer cells around
Using a modified natural substance along with current approaches could improve colon cancer treatment, according to findings by University of California, Irvine biologists.

Uncovering the pathway to colon cancer
The hidden world of genetic changes, or mutations, in healthy colon tissue has been uncovered by scientists at the Wellcome Sanger Institute and their collaborators.

Colon cancer growth reduced by exercise
Exercise may play a role in reducing the growth of colon cancer cells according to new research published in The Journal of Physiology.

Towards a better understanding of how colon cancer develops and progresses
Researchers from the University of Luxembourg have discovered a molecular mechanism that is responsible for the spread of cancer cells in the body and the development of metastases in patients with colon cancer.

New target protein for colon cancer identified
Researchers at Boston University School of Medicine (BUSM) have identified a new potential target protein (c-Cbl) they believe can help further the understanding of colon cancer and ultimately survival of patients with the disease.

Colon cancer -- Targeting tumor cell plasticity
Cell type switch helps colon cancer evade treatment, a study suggests.

A bacterial duo linked to colon cancer
Scientists have identified a combination of bacteria that appears to increase the risk of colon cancer.

New model could speed up colon cancer research
Using the CRISPR gene editing system, MIT researchers have shown they can generate colon tumors in mice that very closely resemble human colon tumors, an advance that should allow scientists to learn more about how the disease progresses and also help them test potential new drugs.

Are dialysis patients being over-screened for colon cancer?
Colonoscopies are being performed more often on healthier dialysis patients than on those with more limited life expectancies; however, overall, dialysis patients are being screened at a much higher rate relative to their life expectancy than their counterparts without kidney failure.

Read More: Colon Cancer News and Colon Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.